BioAge Labs, Inc. (BIOA)

NMS – Real Time Price. Currency in USD

18.19

+0.03 (0.17%)

At close: May 12, 2026, 4:00 PM EDT

18.19

0.00 (0.00%)

After-hours: May 12, 2026, 4:10 PM EDT

09.05.2026

BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease Transcript

08.05.2026

BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials

BioAge Labs NASDAQ: BIOA used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across cardiovascular and retinal disease. Management highlighted phase I clinical results, plans for near-term proof-of-concept studies, and the rationale for pursuing inflammation as a therapeutic target.

08.05.2026

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept trial of BGE-102 in cardiovascular risk planned to initiate in mid-2026, with data anticipated by end of year Phase 1b/2a proof-of-concept trial of BGE-102 in diabetic macular edema (DME) planned to initiate in mid-2026, with data anticipated in mid-2027 Completed upsized follow-on public offering of $132.3 million EMERYVILLE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge” or, "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today provided business updates and reported its first quarter 2026 financial results.

04.05.2026

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET Event will feature Phase 1 clinical data for BGE-102 and the therapeutic rationale for development in atherosclerotic cardiovascular disease (ASCVD) and retinal disease Four leading academic and clinical experts will join BioAge management for presentations, followed by a live question-and-answer session EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that it will host an R&D Day webcast on Friday, May 8, 2026, from 12:30 to 2 PM Eastern Time.

24.04.2026

BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript

21.04.2026

BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans

BioAge Labs Inc (NASDAQ:BIOA) shares are up on Tuesday after the company reported positive Phase 1 data for BGE-102, an oral NLRP3 inhibitor.

21.04.2026

Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know

The mean of analysts' price targets for BioAge Labs, Inc. (BIOA) points to an 183.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Videos

No Data

There is no data to display

Press releases

08.05.2026

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

04.05.2026

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

21.04.2026

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

120 mg and newly announced 60 mg once-daily doses each achieved ≥85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial in cardiovascular risk planned to initiate mid-2026, with results anticipated by end of year Phase 1b/2a proof-of-concept trial in diabetic macular edema (DME) planned to initiate mid-2026, with results anticipated mid-2027 BioAge to host conference call and webcast today at 8:00 AM ET to discuss BGE-102 results EMERYVILLE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today reported results from the Phase 1 clinical trial of BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor.

22.01.2026

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. The gross proceeds from this offering are expected to be approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by BioAge. The offering is expected to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions. In addition, BioAge has granted the underwriters a 30-day option to purchase up to an additional 884,615 shares of common stock in connection with the offering. All of the shares of common stock are being offered by BioAge.

BioAge Labs, Inc. (BIOA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

BioAge Labs, Inc. (BIOA)

BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease Transcript

BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript

BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans

Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know

Videos

No Data

Press releases

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease Transcript

BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript

BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans

Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know

Videos

No Data

Press releases

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

Search stocks

BioAge Labs, Inc. (BIOA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

BioAge Labs, Inc. (BIOA)

BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease Transcript

BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript

BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans

Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know

Videos

No Data

Press releases

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease Transcript

BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript

BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans

Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know

Videos

No Data

Press releases

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

BioAge Announces Pricing of Upsized $115.0 Million Public Offering